Nationwide Fund Advisors purchased a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,796 shares of the biopharmaceutical company’s stock, valued at approximately $161,000.

Several other hedge funds have also recently made changes to their positions in ASMB. JPMorgan Chase & Co. purchased a new position in shares of Assembly Biosciences in the second quarter valued at $3,426,000. AXA purchased a new position in shares of Assembly Biosciences in the second quarter valued at $2,477,000. Goldman Sachs Group Inc. purchased a new position in shares of Assembly Biosciences in the first quarter valued at $1,570,000. Vanguard Group Inc. increased its position in shares of Assembly Biosciences by 11.2% in the first quarter. Vanguard Group Inc. now owns 503,851 shares of the biopharmaceutical company’s stock valued at $12,843,000 after buying an additional 50,615 shares in the last quarter. Finally, TIAA CREF Investment Management LLC purchased a new position in shares of Assembly Biosciences in the second quarter valued at $930,000. Institutional investors and hedge funds own 62.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/18/nationwide-fund-advisors-takes-position-in-assembly-biosciences-inc-asmb.html.

Shares of Assembly Biosciences, Inc. (ASMB) opened at $35.54 on Friday. Assembly Biosciences, Inc. has a 52-week low of $11.07 and a 52-week high of $36.90.

A number of research analysts have recently weighed in on the company. BidaskClub upgraded Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 3rd. Jefferies Group LLC assumed coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They set a “buy” rating and a $50.00 price objective for the company. Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research report on Wednesday. Finally, Chardan Capital reiterated a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th.

In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 19.60% of the company’s stock.

Assembly Biosciences Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Stock Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related stocks with our FREE daily email newsletter.